<SEC-DOCUMENT>0000950103-22-018815.txt : 20221101
<SEC-HEADER>0000950103-22-018815.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101072208
ACCESSION NUMBER:		0000950103-22-018815
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20221101
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		221348488

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp183562_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of November 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39071</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Biop&ocirc;le</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Route de la Corniche
3B</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>1066 Epalinges</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Indicate by check
mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 10pt">&#9746;</FONT></P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 14%"><FONT STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 4.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics Appoints Kristen Harrington-Smith
as Chief Commercial Officer and Peter Graham as Chief Legal Officer</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LAUSANNE, Switzerland,
November 1, 2022</B> &ndash; ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial
Officer, effective November 17, 2022. The Company also announced the appointment of <FONT STYLE="color: #242424; background-color: white">Peter
Graham as Chief Legal Officer, effective November 1, 2022. Both Ms. Harrington-Smith and Mr. Graham will serve on the Company&rsquo;s
leadership team. </FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Kristen Harrington-Smith appointed
as Chief Commercial Officer</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #242424"><FONT STYLE="font-size: 10pt; background-color: white">Ms.
Harrington-Smith is a seasoned leader with over 20 years of experience in the pharmaceutical industry. Most recently, she has served
as Chief Commercial Officer of Immunogen where she has been responsible for building the commercial organization and preparing for the
launch of its first commercial product. Prior to that, she served as Vice President and Head, US Hematology at Novartis Pharmaceuticals,
where she led the teams responsible for a portfolio of therapies in both malignant and non-malignant hematologic diseases </FONT><FONT STYLE="font-size: 10pt">including
diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. In previous roles
of increasing seniority at Novartis, Ms. Harrington-Smith was Vice President and Head, US CAR-T, responsible for the commercial <FONT STYLE="background-color: white">launch
of Kymriah&reg;, the first CAR-T cell therapy for both DLBCL and acute lymphoblastic leukemia, building the management, sales, marketing,
and market access teams, and supporting the launch of Gilenya&reg; for the treatment of multiple sclerosis. Ms. Harrington-Smith received
</FONT>an MBA from the Kenan-Flagler Business School at the University of North Carolina <FONT STYLE="background-color: white">and a
BA from Williams College.</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #242424"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Peter Graham appointed as Chief Legal
Officer</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Graham is a
senior legal executive with over 25 years of legal, compliance and executive management experience primarily in publicly traded biotechnology,
pharmaceutical and medical device companies. From 2015 until its sale to Halozyme Therapeutics, Inc. in 2022, Mr. Graham served as Executive
Vice President, General Counsel, Chief Compliance Officer, Human Resources and Secretary for Antares Pharma, Inc., a commercial-stage
specialty pharmaceutical and combination product company. Previously, he served as Executive Vice President, General Counsel, Chief Compliance
Officer and Global Human Resources at Delcath Systems, Inc., a combination products company focused on cancers of the liver. Earlier
in his career, Mr. Graham held various legal and compliance executive leadership roles at ACIST Medical Systems, Inc., E-Z-EM, Inc.,
and AngioDynamics, Inc. Mr. Graham received his J.D. from Yeshiva University&rsquo;s Benjamin N. Cardozo School of Law and his BA in
Political Science from the University of Wisconsin-Madison.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About ADC Therapeutics</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted
antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm
for patients with hematologic malignancies and solid tumors.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics&rsquo;
CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large
b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab
tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial
for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical
development.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics
is based in Lausanne (Biop&ocirc;le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ZYNLONTA&reg; is a registered trademark
of ADC Therapeutics SA.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This Report on
Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos.&nbsp;<B><U>333-256807,</U></B>&nbsp;333-267293
and 333-267295) of ADC Therapeutics SA and to be a part thereof from the date on which this report is filed, to the extent not superseded
by documents or reports subsequently filed or furnished.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: November 1, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President and General Counsel</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !E +(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH ***0D $D@ =2: *>JZK9:+ITM_J$XAMX\;F//7H .YKF?^%J>$O\ H(2?
M]^'_ ,*\N^)?C,^(]6^Q6<F=-M&(3'25^A;Z=A_]>N%KUZ. BX)U-SS*N-:E
M:&Q]&Q?%#PI-,D27[EG8*/W#]3^%:?\ PF6A_P#/V?\ OVW^%?-&G?\ (3M?
M^NJ_SKO\'T-;K+J3ZL\O%9M7HR2BEK_7<]97QCH;''VS'UC;_"KMOKNEW1 A
MOX&)[%L'\C7C.#Z&DSBD\MI]&SFCGU=/WHI_>>[@@C(.117C6G:]J6EN#;7+
MA!_RS;E3^%>A>'_%MMK!6"8""[[+GY7^G^%<%? U*2YEJCV<)FU'$/D?NR\_
M\SHZ@N[VUL+=I[N>."(=6D; K$\5^++7PS9@D"6\D'[J'/ZGT'\Z\5U?6]0U
MN[-Q?7#2-_"O15'H!VHPV#E6]YZ(K&YE##ODCK+\O4]2U+XI:1:L4LH)KMA_
M%]Q?UY_2L&7XM7Y)\G3;91VWLS?RQ7GBHSL%12S'@ #K6[:>"_$-X@>+2Y@I
MY!DPG\\5Z?U3#4U[WXL\-YAC:S]Q_<O^'.EB^+6H@_OM.M6'^P67^9-;VF_%
M/2KI@E[;S6C'^(?.OZ<_I7GUSX(\1VJ%WTN5E')\LA_T!-8,D4D,A21&1QP5
M88(H^JX:HO=_!A_:&-HOWV_FO^ CZ3M+RVO[=9[2>.:)NCHV14]?/&@ZYJ6B
M7Z2Z?(Q9B T/59/8BO?[&>6ZL8)YK=K>5T#-$_5#Z5Y6*PKH/>Z9]!@<<L4G
MI9K[BQ1117&>B%%%% !1110 5YC\5_&G]FV9T&PDQ=W"_P"D.I_U<9_A^I_E
M]:Z_Q?XGM_"NA2WTN&G;Y+>(G[[_ . ZFOFB^O;C4;Z:\NI#)/,Y=W/<FO1P
M.'YY>TELC@Q=?E7)'=D !9@J@DDX '>I;JUFLKJ6VN(S'-$Q5T/52.HKTCX3
M>#O[2OO[>OH\VMLV+=6'$D@[_1?Y_2N,\8_\CGK/_7Y+_P"A&O6C64JCIKH>
M;*DXTU-]1GA,!O%VD!@"#=QY!_WA7U!]DMO^?>+_ +X%?,'A+_D;](_Z^X__
M $(5]2UYN8MJ4?0[\"DXNZ*SZ?92@B2S@8'UC!K*OO!^CWB$+;^0_9HCC'X=
M*WJ*\Z-6<'>+9UU,/1J*TXI_(\CU[PS=Z&^]OWMLQPLJC]#Z&L5'9'#H2K Y
M!':O<+NTAOK22VG4-'(N"*\9U.R?3M2GM'Y,3D9]1V/Y5[N#Q+K)QENCX_-,
MO6%DIT_A?X/^MC#UZ>ZO-0:[NYFF>0 ;F[8'2H=(TFZUK4HK&T3=)(>IZ*.Y
M/M5^]B\VT<=P-P_"O1?ACHJV6AMJ4B_O[LG:3V0' _,Y/Y5MB*JH4[KY&6!H
M/%UN63\V;?AWPCIOAV!?*C66ZQ\]PX^8GV]!6_117S4YRF^:3NS[BG3A3CRP
M5D%8?B/PMI_B*T9)XU2Y _=W"CYE/OZCVK<HHA.4'S1=F.I3C4BXS5TSE/"G
M@>S\/*+B;;<WYZR$<)[*/ZUU=%%.I4E4ES2>I-&C"C'DIJR"BBBH-0HHHH *
MJWNHVFGQ[[J=(QV!/)^@ZFL'Q)XMCTLM:V>V2[Z,W41_XFN >YGO;AIKB5I9
M&/+,<UY>)S&-)\D-7^"/9P>53K1]I4TC^+*OBNTO_&.N-=7-TL%G'\EO"HW%
M5]3VR>I_^M6?'X!LSC=>W!^BJ*UY-5L+2589;A3,Q"K$GS.2>@P*[:V\*7K1
MJSM''D9VDG(^O%"QV9RBG&Z72R27XH<\#E<)-2LWUNVW^#)M)UVVTVP@L8K$
M16\*!$"-T KQGQCHFI?V_J.HK:2/:SW#RJZ?-A22>0.E>SMX7NT'RO$WXG_"
MN;&KZ:-0FL#>PK=0R&-XW;:=P."!GK^%%#,<?A9.<H<RZZ?JCFQ&#P6(BHQE
MROIK^C/*_"7_ "-^D?\ 7W'_ .A"OJ6O*G\/::^KVNIB 17,$RR[HN-^#G!'
M0_6O2K/4;>^3,3X;NAZBO1>;T,=RN&C[/].YYT<OJX5/FU7=?UH6Z***L KS
M#Q[$(_$.\?\ +2)6/ZC^E>GUYAX]E$GB'8#_ *N)5/ZG^M>AEU_;?)GB9Y;Z
MKKW7ZG+XR,'OQ7LV@0+;^'M.A7HMN@_\=%>-#K7LGAZX2[\/6$T9RIA4?D,'
M^5;YE53:IK=:O\E]^IR9#1DE.L]GHO.VKMZ75_-FE1117D'TP4444 %%%% !
M1110 5S?BSQ!_9-K]GMV_P!+F'!_N+Z_7TKI*\J^(%Q':ZY<3S-A$C4G\AQ7
M%CJE2%*U/=M+[ST<MI4ZE:]7X8IO[NYSEW>1VT3W%S)@9R2>23_4UR6H^([J
M[S' Q@@]%/S-]35+4M1FU*Y,DAP@^XG91_C6MX,\+S>*M?CLURMLGSW$@_A3
M_$]!7J9;DM+"0]MB-9[^2_S?G]W<X<TSRKBY^QPSM#;S?^2\OO[';?"3P=Y\
MW_"1W\?[N,D6BL/O-W?\.@]_I7LU16MM#96L5K;QK'#$@1$4< #I4M%>LZLW
M)G/1I*G#E05\N>,?^1RUG_K\E_\ 0C7U'7RYXP_Y'+6?^OR7_P!"-=F6_'+T
M_4Y,?\,?4O>#M;U*/7;#3A=.UK/.D31R?, "<<9Z5[/=Z/>6+^9#EU'(9.HK
MPCPF0/%VD$D "[CY/^\*^H/M,'_/:/\ [Z%<&;Y;0J5%.,>63ZK]3JRS&U*<
M&F[KLSF+7Q+<6^$N4\U1WZ-6O!XBTV<<S^4WI(,?KTI;Z+1YU)NI+=3_ 'O,
M"FN.U=M ME8V^H22OV1%W#\^!7FT\/CXZ07.OZ_K<]*IB\NM>K+D?]=/^ =O
M/K%A;VTD[7<+*BDX5P2?8"O(=1NY-1U&>[DX:5RV/0=A227I<8VG\ZA19)Y5
MCC0L[G 51DDUZN&AF<;J-.,;]6[V^2/!Q]?)*J3G5E-+[,5:[\V]BK?3""T?
M'WF^45V_PMUY);.71IGQ+$3)#G^)3U'X'G\:X;Q1I-_I%['#>Q[59 T9!R#G
MKSZCI61:7<]C=1W5M(T<T;;D9>H->M3P4/8./-S2EJY=W_ET2Z(\2IF518E3
M<.2,=%!;*/;S;W;>[/I:BN&\.?$C3]0B2#5&6TN@,%S_ *M_?/;\:[6&XAN$
M#P2QRJ?XD8$?I7CU*4Z;M)'TU'$4JT>:F[DE%1S7$-LA>>:.)!U9V"C]:X3Q
M1\2+2SA>UT9Q<7)&// ^1/<>I_2BE1G5=HH5?$TJ$>:H_P#,[^BO%O#7Q"O]
M(D$-^SWEFQR=QRZ9[@GK]#^E>O:;J=IJ]BEY92B2%^^,$'T(]:TKX:=%Z[=S
M'"8ZEB5[NC[%NBBBN8[@) &2< 5\Y_$CQ'#KOB><63[K2$A PZ2,!@M]/2OH
M6]M(K^RFM)]_E3*4?8Q4D'KR.17)_P#"K/"/_0.?_O\ O_C75AIT82YZBNUM
M_F<]=591<*;LGO\ Y'SS;V\MW<QV\$;232L$1%'+$]!7TKX)\*Q>%-!CM<*U
MW+A[F0?Q-Z#V'3_]=)I/@'PYHFHQW]E8;;B,'8S2,VW/&0">M=+6V+Q?M4HQ
MV,L-AO9OFEN%%%%>>=H5\N>,/^1RUG_K\E_]"-?4=<;?_##PUJ-_<7MQ!<&:
M>0R.1,0,DY-=N#KQHR;EU.3%4958I1/GS3O^0G:_]=5_G7?[F]37?Q?"CPM#
M,DJ6]SN1@PS.>HK4_P"$'T3_ )XR_P#?PUZ2S&CYGA8K*:]62<;:>?\ P#RS
M)]32=:]57P3H:G/V>0_60UH6WA_2;0AH;"$,.C,-Q_6E+,J2V39S0R+$-^])
M+[V>7:9X>U+57'V>W81GK(_"C\:]$T#PK:Z*!*Q$UV1S(1POT']:WP !@# H
MKSZ^-J55RK1'MX/*J.'?._>EW?Z(SM:T2RU[3VM+V/<IY1Q]Y#Z@UXUXB\$Z
MIH$C2>6;FS[3QC( _P!H=J]VH(R,'I48?%3HZ+5=C;%X"EB=7I+N?,=/2:6(
MYCD=3_LG%>]:CX+T#5&+S:>B2'J\/R'].*P9?A3H[L3%>7D8]"5/]*]2.846
MO>NCP9Y-B(OW6G\['DDD\LIS)(['_:.:CZUZ_%\*='1@9;R\D'H"H_I70:9X
M.T+26#V]@C2CI)+\Y'TST_"E+,*27NW80R;$2?OM+YW/+_#?@6\U0?;=062U
MTY!O9BIWN!_='7\?YUZYI4NF16T-EI[(L:(=D0!! 7&<YYSEAU]:T&571D89
M5A@CVJO!I]I;3M/# J2L-I8=2/\ (KRZ^)E6^+Y(^@PF"AAE[FK>[+-%%%<I
MW!1110 4444 %%%% !5"YU5;698GM+IBS[$94!#'&>.?8U?K/U,$W&F\?\O0
M_P#0'K.HVHW3-:2BY6DOZU)XKU)9DA,<D<C1F3:ZX( ..:2?4(;?[1OWG[.@
M=P!V.<8_*JES T^O1A9Y8<6K?-'CGYAQR#5&\@:&/65::67-O'\\F,_Q>@%8
MSJSBG\_R-X482:UW2T]78UX+\S2JAL[J,'^)T  _6H%UJ$Q>>;:Z6#&3*8_E
M ]>#G%,LKFU:X14UAKAR"!$63GCV -45M;K_ (1DO]KD,8A+&#8H#*.2N0,\
MCBI=2=O==]^W]?J4J,+VDK:I=>OR_P" ;=Y?P6,"S3,=C,%&T9Z]_ICFB[O4
MLQ%F.21I6VHL8R2<$_R%9LZ3W]]B".%H((=A$I(!9QSC [+@?C4(^TRP:=;M
M*8[FWN#$\@7=T1L'GU&/SJI5I7=OE^%Q1H0LKOU^YV_+\33&JP[)C)'-$\2>
M8T<B88KZCUIT&H&:14^Q7:!OXG0 #]:IWUB\>GWUQ-<//.;=HPQ4*%7K@ >]
M+8W-J9XE76&G<C B+)SQ[ &CGFI*,G^7?^MA.G!P<HJ_W]O3\R_%>Q36/VQ-
MWE;2W(YP/_U57GU>.!8W-K<O')MVNB @EN@Z^]9\%W!:Z$]C+(!=HCQ^3_&Q
M).,#J<U:O(GCTFQC8?.DMN& ]F7-'M9.-T^GXC]C&,K-:7LO2VY<COD=X4>*
M6)Y=VU9%P?EZ]_>HGU:)2Y2"XEBC)#RQIE1CKWR<>P-)> G5K#']V7GTX%5K
M'4+:PTR.UN7"7$";&B(^9R.ZCOGKQZTW4:=F[>?W$JG%Q4DK^7S9=EU&)#&L
M227#R)O580#\OKR0,5+:W4=W$7CW#:Q5E8892.Q%9<[PB6W>Z+Z=,81ME1@%
M'/*'(QQQUJWI,[SQSEG65%DPDZIM\T8'/OZ9'I3A4;G9_P!?J*=)*GS)?U=_
M)_+4T****Z#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
